Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) Skyrockets on FDA Approval for AR-301 Phase 3 Study
Shares of Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS) skyrocketed 97.30% on Wednesday to reach $0.37. This remarkable surge comes on the […]
Aridis Pharmaceuticals
